The FDA on Friday approved AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) for adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor therapy, giving the TROP-2-directed antibody-drug conjugate (ADC) its second breast cancer approval in the US.The decision expands the reach of the companies' ADC into a first-line metastatic setting where chemotherapy has been the only treatment alternative for immunotherap

Biogen and its partner Denali Therapeutics said Thursday their investigational LRRK2 inhibitor, dubbed BIIB122 (DNL151), failed to slow disease progression in early-stage Parkinson's disease (PD) in a mid-stage trial — prompting the companies to discontinue development of the small molecule in idiopathic PD.The Phase IIb LUMA study enrolled 648 patients aged 30 to 80 years with early-stage PD with or without LRRK2 mutations, who were randomised to receive either BIIB122 or placebo for a minimum

The FDA on Friday granted accelerated approval to Gilead Sciences' Hepcludex (bulevirtide-gmod) to treat chronic hepatitis delta virus (HDV) infection, making it the first drug cleared in the US for the disease. Approved specifically for adults without cirrhosis or with compensated cirrhosis, Hepcludex is an entry inhibitor that blocks the NTCP receptor on the surface of hepatocytes, preventing both HDV and hepatitis B virus (HBV) from entering liver cells. HDV is considered a "satellite virus"

AstraZeneca is on course to receive the first approval for its oral selective oestrogen receptor degrader (SERD) camizestrant in a major market, after the EMA's Committee for Medicinal Products for Human Use (CHMP) on Friday recommended clearance in the EU. The panel backed authorisation of camizestrant — to be marketed as Etcamah — for the treatment of adults with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer upon detection of ESR1 mutation and wit

SHANGHAI, May 21, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present multiple clinical study results of its novel Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including the Phase Ib/II clinical study data of 9MW2821 in combination with toripalimab for locally advanced or metastatic urothelial carcinoma (la/mUC)

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at

FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company received a delisting notice from The Nasdaq Stock Market LLC (“Nasdaq”). As previously disclosed in the Current Report on Form 8-K filed by the Company on November 25, 2025 with the Securities and Exchange Commission (the “SEC”), on November 19, 2025, the Company received notices from Nasdaq indicating that the Company’s listed securities fa

Contact Timo Lindemann T +49 (0) 6172 608-7939 timo.lindemann@fresenius.com Documents Text as PDF document (PDF, 135 KB) Thanks to its disciplined execution of #FutureFresenius, Fresenius is today stronger than ever before. Rejuvenate is paying off and delivering accelerated performance for long-term value creation. With its combination of operating strength and resilience, Fresenius is today able to actively help shape the healthcare of the future. Shareholders’ trust is to be rewarded: propose

CONSHOHOCKEN, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on May 15, 2026 to 15 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance w

New findings in kidney, liver and prostate cancers reflect the shift toward more personalized, biology-driven treatment. LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope ® , one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, will present new findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, where t